Literature DB >> 22156452

Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.

Birgit Cremer1, Brenda M Sandmaier, Wolfgang Bethge, Thoralf Lange, Valentin Goede, Udo Holtick, Michael Hallek, Kai Hübel.   

Abstract

Allogeneic hematopoietic stem cell transplantation represents a curative treatment approach for a large range of hematologic malignancies. Traditionally, high-dose radiochemotherapy as preparative regimen has been thought to be necessary for successful allogeneic stem cell transplantation. However, high-dose conditioning often results in considerable medullary and extramedullary toxicity, contributing to high rates of treatment-related mortality. This limits the use of this procedure to patients below 60 years of age without significant comorbidities. Since the peak incidence of most hematological malignancies is beyond the 5th decade of life, the majority of patients are not eligible for high-dose treatment. During the last 15 years, several dose-reduced or even non-myeloablative conditioning regimens have been developed, offering a curative treatment option for these patients. This review summarizes the history of reduced-intensity conditioning (RIC) transplantations, depicts the differences among regimens, highlights significant patient factors, and describes the impact on selected hematological malignancies.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 22156452     DOI: 10.1159/000334542

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  1 in total

1.  Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.

Authors:  Gabriel Afram; Jose Antonio Pérez Simón; Mats Remberger; Teresa Caballero-Velázquez; Rodrigo Martino; Jose Luis Piñana; Olle Ringden; Albert Esquirol; Lucia Lopez-Corral; Irene Garcia; Oriana López-Godino; Jordi Sierra; Dolores Caballero; Per Ljungman; Lourdes Vazquez; Hans Hägglund
Journal:  Med Oncol       Date:  2018-04-25       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.